[Activity of plasminogen activator inhibitor (PAI-1) in plasma of women treated after menopause with hormone replacement therapy].
Prospective studies that included 48 postmenopausal women on hormonal replacement therapy (transdermal estradiol and medroxyprogesterone acetate orally) was performed. Plasma activity of plasminogen activator inhibitor (PAI-1), levels of fibrinogen and serum lipids profile was measured before, after 6 and 12 months of continuous treatment. Plasma activity of PAI-1 showed significant decrease after 6 month of therapy. Plasma fibrinogen concentration significantly decreased (p < 0.05) after 12 months of treatment (271.27 +/- 71.08 vs. 238.33 +/- 34.48 mg/dl).
Ciepłuch
R
R
Oddziału ginekologii i połoznictwa Szpitala Miejskiego im. Brudzyńskiego w Gdyni.
Czestochowska
E
E
D000328:Adult; D000368:Aged; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008055:Lipids / Q000097:blood; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D017698:Postmenopause / Q000097:blood* / Q000187:drug effects
D008055:Lipids; D017395:Plasminogen Activator Inhibitor 1; D004958:Estradiol; D005340:Fibrinogen; D017258:Medroxyprogesterone Acetate
Aktywność inhibitora aktywatora plazminogenu (PAI-1) w osoczu kobiet leczonych po menopauzie hormonalna terapia zastepcza.